19 citations
,
March 2022 in “Journal of Infection” Canakinumab's effect on COVID-19 outcomes is unclear.
18 citations
,
August 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Two existing drugs may help treat COVID-19 by inhibiting a key viral protein.
14 citations
,
June 2020 in “Journal of the American Academy of Dermatology” Global collaboration in dermatology improved data sharing and patient care during COVID-19.
12 citations
,
April 2020 in “Medical hypotheses” Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
9 citations
,
July 2021 in “Essays in Biochemistry” Sex hormones may influence COVID-19 severity, with males at higher risk, and certain hormone therapies could potentially treat the virus.
9 citations
,
September 2020 in “Journal of Drugs in Dermatology” Men had worse COVID-19 outcomes than women in New York City.
9 citations
,
January 2020 in “Critical Reviews in Immunology” MAIT cells may help fight COVID-19 but also contribute to severe inflammation.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
8 citations
,
January 2022 in “Infectious diseases News Opinions Training” Genetic differences affect COVID-19 severity and treatment effectiveness.
8 citations
,
September 2020 in “Journal of adolescent health” Gender-affirming care for youth remained essential during the COVID-19 pandemic, with telemedicine playing a key role.
7 citations
,
March 2024 in “PubMed” More social media use during COVID-19 increased interest in cosmetic procedures.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
7 citations
,
December 2021 in “Journal of Infection” One in four people still had symptoms like weight loss, hair loss, and fatigue 12-14 weeks after recovering from COVID-19.
6 citations
,
January 2024 in “Cancers” Antiandrogens don't help with COVID-19 and aren't recommended.
6 citations
,
March 2021 in “Cytotechnology” Mesenchymal stem cells show promise in treating COVID-19 by reducing inflammation and aiding recovery, but more research is needed.
5 citations
,
December 2022 in “Viruses” Antiandrogens may help prevent or treat COVID-19 by blocking virus entry into cells.
5 citations
,
November 2021 in “History & Philosophy of the Life Sciences” Racial minorities faced more Covid-19 blame due to anti-fatness and structural racism.
5 citations
,
May 2020 in “Journal of the American Academy of Dermatology” AGA might indicate higher risk for severe COVID-19.
5 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Hydroxychloroquine might help prevent COVID-19, but more research is needed.
4 citations
,
March 2022 in “Journal of Infection” 18% of COVID-19 survivors experience PTSD, with risk factors including age, gender, smoking, and lung damage.
4 citations
,
May 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Long-lasting COVID-19 symptoms like fatigue and breathing difficulties can persist for over 60 days, requiring ongoing care.
4 citations
,
May 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Migrants from certain regions had a higher risk of COVID-19 than Spaniards.
3 citations
,
November 2022 in “Clinical Cosmetic and Investigational Dermatology” The pandemic changed the types of skin conditions seen, not the number of visits.
3 citations
,
January 2022 in “Journal of Infection” Some early COVID-19 mutations in patients predicted future common virus mutations.
3 citations
,
December 2021 in “Physiological Research” Low testosterone may increase COVID-19 severity in men.
3 citations
,
August 2021 in “Clinical, Cosmetic and Investigational Dermatology” Teledermatology was popular among young adults and women, and high-resolution photos improved service during the pandemic.
3 citations
,
March 2021 in “Indian Journal of Rheumatology” Remote monitoring of chronic diseases like dermatomyositis is challenging and needs better tools for early detection and patient education.
3 citations
,
December 2020 in “Problemy e̊ndokrinologii” Male hormones may make COVID-19 worse, while substances that block these hormones could lessen symptoms.
2 citations
,
July 2024 in “Ibn AL- Haitham Journal For Pure and Applied Science” PCOS women with COVID-19 have higher cardiometabolic risks.
1 citations
,
December 2022 in “BMC Public Health” Long-term effects of COVID-19 can vary over time and are more likely in certain age and gender groups, while race, income, and education levels have little to no impact. Ongoing medical care is needed due to potential complications.